GlassScriptPhysician profile
Jonathan B Rubenstein
NPI 1558413294
$37,161.75
in general payments reported to CMS, 2019-2025
25 companies · $7,826 in 2025
The $7,826 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,874 · 2020: $2,990 · 2021: $4,015 · 2022: $6,473 · 2023: $7,041 · 2024: $4,943 · 2025: $7,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $5,154 · Food and Beverage: $1,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,750.00 |
| Consulting Fee | $5,154.00 |
| Food and Beverage | $1,905.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $19,379.00 | 2019-2025 | Clareon, Ngenuity, Luxor |
| Sight Sciences, INC. | $6,774.82 | 2019-2024 | Omni Surgical System |
| Alcon Research LLC | $6,646.07 | 2019-2023 | Luxor, Clareon |
| Rxsight INC | $1,667.63 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $1,435.13 | 2023-2025 | Envista Mx60 Iol, Teneo, Envista Envy Iol |
| Oyster Point Pharma, INC. | $205.58 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $149.42 | 2019 | |
| Abbvie INC. | $134.06 | 2022-2025 | Durysta |
| Glaukos Corporation | $122.60 | 2021-2024 | Idose |
| Johnson & Johnson Surgical Vision, INC. | $97.91 | 2019-2025 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $91.82 | 2024 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $80.13 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $65.04 | 2019-2020 | |
| Allergan, INC. | $54.78 | 2019-2021 | |
| New World Medical,INC. | $39.95 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.41 | 2019-2023 | |
| Dompe US, INC. | $32.19 | 2025 | Oxervate |
| Spark Therapeutics, INC. | $30.74 | 2022 | |
| Eyevance Pharmaceuticals LLC | $24.42 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.33 | 2019 | |
| Shire North American Group INC | $22.68 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Medtronic Minimed, INC. | $12.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.